TARSUS PHARMACEUTICALS, INC. (TARS)

Every figure this model derived for TARS, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 18,155,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 449,690,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 561,989,000 AssetsCurrent 2026-06-30
current liabilities 175,753,000 LiabilitiesCurrent 2026-06-30
equity 346,732,000 StockholdersEquity 2026-06-30
interest expense 8,766,000 InterestExpenseDebt 2026-06-30
ocf 74,158,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 606,331,000 Revenues 2026-06-30
sbc 51,813,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TARS on one particular measure came for.

RatioValue
cash operating margin0.77
current ratio3.2
current ratio reported3.2
deferred revenue growth-100.0
dilution pct11.12
fcf margin9.24
growth cv1.63
interest cover-5.54
operating margin-8.0
owner earnings margin0.69
revenue growth105.17
revenue growth per share84.64
rule of 4097.17
sbc pct revenue8.55

What to be careful about

What this model itself distrusts about TARS's figures. Written by the derivation as it ran, not added afterwards.